Asbestos in tumours

Our plain-English summary of Asbestos in tumours, by C. Gold (Journal of Clinical Pathology, 1971).

The study

• Author: C. Gold
• Journal: Journal of Clinical Pathology
• Published: 1971;24(5):481
• Cited by: 1 article, as counted by NIH iCite
• Read it: PubMed · Publisher · Free full text

In plain English

This is a short abstract of a talk given at the 86th general meeting of the Association of Clinical Pathologists, by an author at the M.R.C. Pneumoconiosis Unit in Penarth, Glamorgan. It is not a full study report and gives no case numbers or measurements. The author noted that, according to epidemiological evidence, the four main types of asbestos, though all carcinogenic in animals, do not appear equally implicated in human tumours. The author proposed studying the dust in the lungs together with the tissue changes, and illustrated this with selected referred human lung cancers and mesotheliomas. According to the abstract, bronchial carcinomas tended to have a high lung asbestos content, while lungs from pleural mesothelioma cases could contain relatively little asbestos. In peritoneal mesotheliomas the lungs could hold an intermediate or sometimes considerable amount without a pleural or lung tumour. The author described a simple KOH (potassium hydroxide) extraction method that gave a concentrated dust residue for light-microscope study and for identifying asbestos type by electron microscope. The author concluded that, given these apparent paradoxes, such a combined investigation seemed justified.

We wrote this plain-English summary from the full article with the help of AI, and a second AI model checked each sentence against the article. It is not the authors' wording; the abstract and the article are their own account.

What the study did and found

• Design: Conference (meeting) abstract describing a laboratory approach that combines measurement of lung dust with examination of the tissue changes, illustrated with selected cases
• Who was studied: Selected referred human lung cancers and mesotheliomas (number, place and dates not given). The abstract also mentions experimental animal work.
• Exposure: Asbestos found in lung tissue (lung asbestos content). The abstract refers to 'the four main types of asbestos' but does not name them, and gives no doses.
• Main results:
  • Bronchial carcinomas tended to have a high lung asbestos content, while lungs from pleural mesothelioma cases could contain relatively little asbestos (no figures given).
  • In peritoneal mesotheliomas, the lungs could have an intermediate amount, or sometimes a considerable amount, of asbestos without a pleural or intrapulmonary tumour (no figures given).
  • The KOH extraction method gave a concentrated dust residue suitable for quantitative and morphological study with the light microscope, and useful for identifying and typing asbestos with the electron microscope.
  • In experimental animal work with pure exposures to the individual asbestos types, very high fibre counts could be obtained and virtually pure dust recovered.
• The authors' conclusion: The author concluded that, given these apparent paradoxes, a correlative investigation of both the lung dust and the tissue changes seemed justified, including establishing whether human tumours are related only to certain asbestos types or show a dose-response relationship.

Related studies

• Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study — A. Marabelle, M. Fakih, et al. (2020)
• Pembrolizumab in paediatric patients with advanced melanoma or a PD-L1-positive, advanced, relapsed, or refractory solid tumour or lymphoma (KEYNOTE-051): interim analysis of an open-label, single-arm, phase 1-2 trial — B. Geoerger, H.J. Kang, et al. (2020)
• Tumours associated with BAP1 mutations — R. Murali, T. Wiesner, et al. (2013)
• Heterogenous presence of neutrophil extracellular traps in human solid tumours is partially dependent on IL-8 — C.E. de Andrea, M.C. Ochoa, et al. (2021)
• Association of SV40 with human tumours — B. Jasani, A. Cristaudo, et al. (2001)
• A phase Ib dose-finding, pharmacokinetic study of the focal adhesion kinase inhibitor GSK2256098 and trametinib in patients with advanced solid tumours — G. Mak, J.C. Soria, et al. (2019)

Browse more research in Journal of Clinical Pathology, or return to medical research.